Please login to the form below

Not currently logged in
Email:
Password:

Glucagon

This page shows the latest Glucagon news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk boosted by new type 2 diabetes launches

Novo Nordisk boosted by new type 2 diabetes launches

Rapid uptake of newcomer Ozempic aids growth. Novo Nordisk’s expansion into a series of glucagon-like peptide 1 (GLP-1) products has helped boost sales despite loosing ground in the

Latest news

More from news
Approximately 1 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    In fact, diabetes is thought to be the single largest area for oral delivery of biologics, with a number of groups working on oral insulin as well as analogues of glucagon -

  • Deal Watch November 2015 Deal Watch November 2015

    Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... Again this was a global deal (excluding South Korea and China)

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel syndrome.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics